AustralieFrV1, Main, Exploration, bibRecord, 00A302

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial

Identifieur interne : 00A302 ( Main/Exploration ); précédent : 00A301; suivant : 00A303

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial

Auteurs : Howard Feldman [Canada] ; Serge Gauthier [Canada] ; Jane Hecker [Australie] ; Bruno Vellas [France] ; Yikang Xu [États-Unis] ; John R. Ieni [États-Unis] ; Elias M. Schwam [États-Unis]

Source :

International Journal of Geriatric Psychiatry [ 0885-6230 ] ; 2005-06.

RBID : ISTEX:3B7EF2DB4F861B284729EB75D366CD2822A91C16

Descripteurs français

Pascal (Inist)
- Antialzheimer, Cholinesterase, Donépézil, Démence Alzheimer, Essai clinique, Gériatrie, Gérontologie, Homme, Malade état grave, Nootrope, Personne âgée, Placebo, Psychotrope, Randomisation, Sécurité, Toxicité.
Wicri :
- topic : Droit d'auteur, Gérontologie, Homme, Neurologie, Personne âgée, Psychiatrie.

English descriptors

Abstract

There have been very limited investigations of cholinesterase inhibitor therapy in more advanced stages of Alzheimer's disease (AD). The efficacy and safety of donepezil were evaluated in post hoc analyses of a subgroup of patients with more severe AD (standardized Mini‐Mental State Examination [sMMSE] score 5–12) within a randomized, placebo‐controlled trial in moderate to severe AD (MSAD study). Additional analyses examined whether donepezil's treatment effects were consistent across the full range of baseline AD severity studied (sMMSE score 5–17).

Url:

https://api.istex.fr/document/3B7EF2DB4F861B284729EB75D366CD2822A91C16/fulltext/pdf

DOI: 10.1002/gps.1325

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial</title>
<author><name sortKey="Feldman, Howard" sort="Feldman, Howard" uniqKey="Feldman H" first="Howard" last="Feldman">Howard Feldman</name>
</author>
<author><name sortKey="Gauthier, Serge" sort="Gauthier, Serge" uniqKey="Gauthier S" first="Serge" last="Gauthier">Serge Gauthier</name>
</author>
<author><name sortKey="Hecker, Jane" sort="Hecker, Jane" uniqKey="Hecker J" first="Jane" last="Hecker">Jane Hecker</name>
</author>
<author><name sortKey="Vellas, Bruno" sort="Vellas, Bruno" uniqKey="Vellas B" first="Bruno" last="Vellas">Bruno Vellas</name>
</author>
<author><name sortKey="Xu, Yikang" sort="Xu, Yikang" uniqKey="Xu Y" first="Yikang" last="Xu">Yikang Xu</name>
</author>
<author><name sortKey="Ieni, John R" sort="Ieni, John R" uniqKey="Ieni J" first="John R." last="Ieni">John R. Ieni</name>
</author>
<author><name sortKey="Schwam, Elias M" sort="Schwam, Elias M" uniqKey="Schwam E" first="Elias M." last="Schwam">Elias M. Schwam</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:3B7EF2DB4F861B284729EB75D366CD2822A91C16</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/gps.1325</idno>
<idno type="url">https://api.istex.fr/document/3B7EF2DB4F861B284729EB75D366CD2822A91C16/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000B14</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000B14</idno>
<idno type="wicri:Area/Istex/Curation">000B14</idno>
<idno type="wicri:Area/Istex/Checkpoint">001860</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001860</idno>
<idno type="wicri:doubleKey">0885-6230:2005:Feldman H:efficacy:and:safety</idno>
<idno type="wicri:Area/Main/Merge">00AE68</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:05-0279471</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">004921</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001782</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">004635</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">004635</idno>
<idno type="wicri:doubleKey">0885-6230:2005:Feldman H:efficacy:and:safety</idno>
<idno type="wicri:Area/Main/Merge">00B285</idno>
<idno type="wicri:Area/Main/Curation">00A302</idno>
<idno type="wicri:Area/Main/Exploration">00A302</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial</title>
<author><name sortKey="Feldman, Howard" sort="Feldman, Howard" uniqKey="Feldman H" first="Howard" last="Feldman">Howard Feldman</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of British Columbia, Clinic for Alzheimer's Disease and Related Disorders, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Canada</country>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Correspondence address: Division of Neurology, University of British Columbia Hospital, S192‐2211 Wesbrook Mall, Vancouver, BC, V6T2B5</wicri:regionArea>
<wicri:noRegion>V6T2B5</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gauthier, Serge" sort="Gauthier, Serge" uniqKey="Gauthier S" first="Serge" last="Gauthier">Serge Gauthier</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Alzheimer Disease Research Unit, McGill Centre for Studies in Aging, Verdun, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hecker, Jane" sort="Hecker, Jane" uniqKey="Hecker J" first="Jane" last="Hecker">Jane Hecker</name>
<affiliation wicri:level="1"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Rehabilitation and Aged Care, Repatriation General Hospital, Daw Park, SA</wicri:regionArea>
<wicri:noRegion>SA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vellas, Bruno" sort="Vellas, Bruno" uniqKey="Vellas B" first="Bruno" last="Vellas">Bruno Vellas</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Toulouse University Alzheimer's Center, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Xu, Yikang" sort="Xu, Yikang" uniqKey="Xu Y" first="Yikang" last="Xu">Yikang Xu</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Biometrics Department, Pfizer Global Pharmaceuticals, Pfizer Inc, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ieni, John R" sort="Ieni, John R" uniqKey="Ieni J" first="John R." last="Ieni">John R. Ieni</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Medical Affairs Department, Eisai Inc, Teaneck, NJ</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schwam, Elias M" sort="Schwam, Elias M" uniqKey="Schwam E" first="Elias M." last="Schwam">Elias M. Schwam</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Alzheimer's Disease Management Team, Pfizer Global Pharmaceuticals, Pfizer Inc, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">International Journal of Geriatric Psychiatry</title>
<title level="j" type="alt">INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY</title>
<idno type="ISSN">0885-6230</idno>
<idno type="eISSN">1099-1166</idno>
<imprint><biblScope unit="vol">20</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="559">559</biblScope>
<biblScope unit="page" to="569">569</biblScope>
<biblScope unit="page-count">11</biblScope>
<publisher>John Wiley & Sons, Ltd.</publisher>
<pubPlace>Chichester, UK</pubPlace>
<date type="published" when="2005-06">2005-06</date>
</imprint>
<idno type="ISSN">0885-6230</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-6230</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer</term>
<term>Alzheimer disease</term>
<term>Antialzheimer agent</term>
<term>Assoc disord</term>
<term>Baseline</term>
<term>Baseline scores</term>
<term>Baseline smmse score</term>
<term>Caregiver</term>
<term>Caregiver burden</term>
<term>Caregiver input</term>
<term>Cholinergic</term>
<term>Cholinesterase</term>
<term>Clinical trial</term>
<term>Cognition</term>
<term>Cohort</term>
<term>Copyright</term>
<term>Critically ill</term>
<term>Dementia</term>
<term>Disability assessment</term>
<term>Donepezil</term>
<term>Donepezil group</term>
<term>Donepezil treatment</term>
<term>Elderly</term>
<term>Feldman</term>
<term>Galantamine</term>
<term>Gauthier</term>
<term>Geriatr</term>
<term>Geriatr psychiatry</term>
<term>Geriatrics</term>
<term>Gerontology</term>
<term>Human</term>
<term>Iadl</term>
<term>Iadl psms</term>
<term>Impairment</term>
<term>John wiley sons</term>
<term>Last observation</term>
<term>Locf</term>
<term>Medication</term>
<term>Memantine</term>
<term>Mmse</term>
<term>Mmse range</term>
<term>Mmse score</term>
<term>Msad</term>
<term>Msad study</term>
<term>National institute</term>
<term>Ndings</term>
<term>Neurology</term>
<term>Neuropsychiatric</term>
<term>Neuropsychiatric inventory</term>
<term>Neuropsychiatric symptoms</term>
<term>Nootropic agent</term>
<term>Placebo</term>
<term>Placebo group</term>
<term>Psms</term>
<term>Psychiatry</term>
<term>Psychoactive medications</term>
<term>Psychotropic</term>
<term>Randomization</term>
<term>Randomized</term>
<term>Safety</term>
<term>Severe disease</term>
<term>Severe impairment battery</term>
<term>Side effects</term>
<term>Smmse</term>
<term>Smmse score</term>
<term>Standardized state examination</term>
<term>State examination</term>
<term>Study medication</term>
<term>Subgroup</term>
<term>Subgroup analysis</term>
<term>Toxicity</term>
<term>Treatment difference</term>
<term>Treatment disease severity interaction</term>
<term>Treatment effects</term>
<term>Treatment groups</term>
<term>Treatment severity interaction</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antialzheimer</term>
<term>Cholinesterase</term>
<term>Donépézil</term>
<term>Démence Alzheimer</term>
<term>Essai clinique</term>
<term>Gériatrie</term>
<term>Gérontologie</term>
<term>Homme</term>
<term>Malade état grave</term>
<term>Nootrope</term>
<term>Personne âgée</term>
<term>Placebo</term>
<term>Psychotrope</term>
<term>Randomisation</term>
<term>Sécurité</term>
<term>Toxicité</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Alzheimer</term>
<term>Assoc disord</term>
<term>Baseline</term>
<term>Baseline scores</term>
<term>Baseline smmse score</term>
<term>Caregiver</term>
<term>Caregiver burden</term>
<term>Caregiver input</term>
<term>Cholinergic</term>
<term>Cognition</term>
<term>Cohort</term>
<term>Copyright</term>
<term>Dementia</term>
<term>Disability assessment</term>
<term>Donepezil</term>
<term>Donepezil group</term>
<term>Donepezil treatment</term>
<term>Feldman</term>
<term>Galantamine</term>
<term>Gauthier</term>
<term>Geriatr</term>
<term>Geriatr psychiatry</term>
<term>Iadl</term>
<term>Iadl psms</term>
<term>Impairment</term>
<term>John wiley sons</term>
<term>Last observation</term>
<term>Locf</term>
<term>Medication</term>
<term>Memantine</term>
<term>Mmse</term>
<term>Mmse range</term>
<term>Mmse score</term>
<term>Msad</term>
<term>Msad study</term>
<term>National institute</term>
<term>Ndings</term>
<term>Neurology</term>
<term>Neuropsychiatric</term>
<term>Neuropsychiatric inventory</term>
<term>Neuropsychiatric symptoms</term>
<term>Placebo</term>
<term>Placebo group</term>
<term>Psms</term>
<term>Psychiatry</term>
<term>Psychoactive medications</term>
<term>Randomized</term>
<term>Severe disease</term>
<term>Severe impairment battery</term>
<term>Side effects</term>
<term>Smmse</term>
<term>Smmse score</term>
<term>Standardized state examination</term>
<term>State examination</term>
<term>Study medication</term>
<term>Subgroup</term>
<term>Subgroup analysis</term>
<term>Treatment difference</term>
<term>Treatment disease severity interaction</term>
<term>Treatment effects</term>
<term>Treatment groups</term>
<term>Treatment severity interaction</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Droit d'auteur</term>
<term>Gérontologie</term>
<term>Homme</term>
<term>Neurologie</term>
<term>Personne âgée</term>
<term>Psychiatrie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">There have been very limited investigations of cholinesterase inhibitor therapy in more advanced stages of Alzheimer's disease (AD). The efficacy and safety of donepezil were evaluated in post hoc analyses of a subgroup of patients with more severe AD (standardized Mini‐Mental State Examination [sMMSE] score 5–12) within a randomized, placebo‐controlled trial in moderate to severe AD (MSAD study). Additional analyses examined whether donepezil's treatment effects were consistent across the full range of baseline AD severity studied (sMMSE score 5–17).</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>Canada</li>
<li>France</li>
<li>États-Unis</li>
</country>
<region><li>Midi-Pyrénées</li>
<li>New Jersey</li>
<li>Occitanie (région administrative)</li>
<li>État de New York</li>
</region>
<settlement><li>Toulouse</li>
</settlement>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Feldman, Howard" sort="Feldman, Howard" uniqKey="Feldman H" first="Howard" last="Feldman">Howard Feldman</name>
</noRegion>
<name sortKey="Feldman, Howard" sort="Feldman, Howard" uniqKey="Feldman H" first="Howard" last="Feldman">Howard Feldman</name>
<name sortKey="Feldman, Howard" sort="Feldman, Howard" uniqKey="Feldman H" first="Howard" last="Feldman">Howard Feldman</name>
<name sortKey="Gauthier, Serge" sort="Gauthier, Serge" uniqKey="Gauthier S" first="Serge" last="Gauthier">Serge Gauthier</name>
</country>
<country name="Australie"><noRegion><name sortKey="Hecker, Jane" sort="Hecker, Jane" uniqKey="Hecker J" first="Jane" last="Hecker">Jane Hecker</name>
</noRegion>
</country>
<country name="France"><region name="Occitanie (région administrative)"><name sortKey="Vellas, Bruno" sort="Vellas, Bruno" uniqKey="Vellas B" first="Bruno" last="Vellas">Bruno Vellas</name>
</region>
</country>
<country name="États-Unis"><region name="État de New York"><name sortKey="Xu, Yikang" sort="Xu, Yikang" uniqKey="Xu Y" first="Yikang" last="Xu">Yikang Xu</name>
</region>
<name sortKey="Ieni, John R" sort="Ieni, John R" uniqKey="Ieni J" first="John R." last="Ieni">John R. Ieni</name>
<name sortKey="Schwam, Elias M" sort="Schwam, Elias M" uniqKey="Schwam E" first="Elias M." last="Schwam">Elias M. Schwam</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00A302 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00A302 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:3B7EF2DB4F861B284729EB75D366CD2822A91C16
   |texte=   Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.